Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2014-06-16 Interim / Quarterly Rep…
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2014
2014-06-16 English
Regulatory Filings 2014
Regulatory Filings Classification · 90% confidence The provided document text appears to be an encoded or corrupted file content rather than readable text. There are no discernible keywords, regulatory references, fiscal period dates, or document titles that indicate the nature of the filing. The document length is 15,000 characters, which is substantial, but the content does not contain any meaningful information to classify it as a specific report type. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS).
2014-06-13 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement filed under Schedule 14A pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals for election of directors, ratification of auditors, amendments to the certificate of incorporation, and other business to be transacted at the meeting. The document is clearly a solicitation of proxies and contains detailed proxy materials for the Annual Meeting. It is not an announcement of voting results, nor is it a report of financial results or management discussion. The presence of detailed proposals and voting instructions confirms this is a Proxy Solicitation & Information Statement. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the full proxy statement, not just an announcement or notice.
2014-06-03 English
PRIMARY DOCUMENT
Director's Dealing
2014-05-30 English
Regulatory Filings 2014
Regulatory Filings
2014-05-09 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from the company's CEO to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is correspondence related to a capital raising filing but does not contain financial data or the registration statement itself. The document is short (875 characters) and is a regulatory communication rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2014-05-06 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.